Table 3 Univariate analysis evaluating the factors associated with increase(s) in cisatracurium dosage
From: How to reduce cisatracurium consumption in ARDS patients: the TOF-ARDS study
Variables | No cisatracurium dosage increase N = 18 | Cisatracurium dosage increases N = 12 | p value |
|---|---|---|---|
Age, years | 64 (47–70) | 63 (53–76) | 0.54 |
Female, n (%) | 5 (28) | 2 (17) | 0.67 |
Height, cms | 170 (160–175) | 170 (161–174) | 0.66 |
Weight, kgs | 74 (59–86) | 82 (68–110) | 0.14 |
SAPS 2 | 47 (28–54) | 44 (41–53) | 0.78 |
SOFA | 8 (7–12) | 8 (7–10) | 0.37 |
Characteristics at day 1 | |||
Vt, mL | 410 (380–420) | 390 (360–437) | 0.60 |
Vt, mL/kg (PBW) | 6.2 (5.6–6.8) | 6.2 (5.4–6.78) | 0.85 |
Respiratory rate | 26 (22–28) | 24 (20–27) | 0.25 |
PEEP, cm H20 | 12 (10–14) | 8 (8–11.5) | 0.008 |
Pplat, cm H20 | 25 (22–26) | 25 (22–27) | 0.92 |
Driving pressure, cm H2O | 12 (10–15) | 15 (13–16) | 0.017 |
PaO2/FiO2 ratio | 92 (70–119) | 107 (100–121) | 0.14 |
Severe versus moderate ARDS, n (%) | 10 (55) | 3 (25) | 0.14 |
pH | 7.32 (7.22–7.36) | 7.33 (7.30–7.42) | 0.49 |
PaCO2, mmHg | 47 (39–57) | 44 (41–57) | 0.92 |
Prone position, n (%) | 10 (55) | 3 (25) | 0.14 |
Bicarbonates, mmol/L | 24 (21–29) | 27 (24–32) | 0.15 |
Lactate, mmol/L | 1.28 (1.10–1.91) | 1.27 (0.97–2.22) | 0.87 |
Vasopressor use, n (%) | 17 (94) | 10 (83) | 0.55 |
Norepinephrine, mg/h | 1.1 (0.55–2.5) | 1 (0.0–1.7) | 0.32 |
Body temperature, °C | 38.1 (37.5–38.6) | 38.1 (37.4–38.6) | 0.95 |
Ketamine use, n (%) | 5 (28) | 4 (33) | 1 |
Other organ failure, (n 0/1/2/>2) | 1/13/4/0 | 3/4/4/1 | 0.12 |